U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H30O3
Molecular Weight 366.4941
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DROSPIRENONE

SMILES

C[C@@]12CCC(=O)C=C2[C@]3([H])C[C@]3([H])[C@]4([H])[C@]1([H])CC[C@@]5(C)[C@@]4([H])[C@]6([H])C[C@]6([H])[C@]75CCC(=O)O7

InChI

InChIKey=METQSPRSQINEEU-HXCATZOESA-N
InChI=1S/C24H30O3/c1-22-6-3-12(25)9-17(22)13-10-14(13)20-16(22)4-7-23(2)21(20)15-11-18(15)24(23)8-5-19(26)27-24/h9,13-16,18,20-21H,3-8,10-11H2,1-2H3/t13-,14+,15-,16+,18+,20-,21+,22-,23+,24+/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7625729 | https://www.ncbi.nlm.nih.gov/pubmed/23530659 | https://www.ncbi.nlm.nih.gov/pubmed/7107766 | http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021355s006lbl.pdf

Drospirenone (INN, USAN), also known as 1,2-dihydrospirorenone, is a steroidal progestin of the spirolactone group. Drospirenone binds strongly to the progesterone receptor (PR) and mineralocorticoid receptor (MR), with lower affinity, to the androgen receptor (AR), and very low affinity for the glucocorticoid receptor (GR). Drospirenone is an ingredient in some birth control pills and hormone replacement therapy. In combination with ethinylestradiol it is used as contraception, and for women who want contraception it is also approved by the U.S. Food and Drug Administration (FDA) to treat vasomotor symptoms due to menopause.It is sold as a combined oral contraceptive under the brand names Yasmin (US, EU, Latin America), Jasmine (France), Yarina (Russia) in a dosage containing drospirenone 3 mg/ethinylestradiol 30 µg. In the United States, Bayer Schering released a pill based on Yasmin with the B vitamin folate (B9), which is marketed under the names Safyral and Beyaz.

Originator

Curator's Comment:: # Bayer HealthCare Pharmaceuticals

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
YASMIN

Approved Use

INDICATIONS AND USAGE. Yasmin is an estrogen/progestin COC indicated for use by women to prevent pregnancy

Launch Date

9.8953921E11
Primary
Angeliq

Approved Use

Indications and Usage ANGELIQ is indicated in women who have a uterus for the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.

Launch Date

1.12777914E12
Primary
Angeliq

Approved Use

Indications and Usage ANGELIQ is indicated in women who have a uterus for the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.

Launch Date

1.12777914E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
62.5 ng/mL
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
9.85 ng/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
33.9 ng/mL
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
27 ng/mL
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
41 ng/mL
4 mg 1 times / day steady-state, oral
dose: 4 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1007 ng × h/mL
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
140 ng × h/mL
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
506 ng × h/mL
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
26.3 h
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
25.5 h
1 mg single, oral
dose: 1 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
28.5 h
3 mg single, oral
dose: 3 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
30 h
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
30 h
4 mg 1 times / day steady-state, oral
dose: 4 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4%
4 mg single, oral
dose: 4 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
DROSPIRENONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
healthy, 17 - 40 years
n = 2837
Health Status: healthy
Age Group: 17 - 40 years
Sex: F
Population Size: 2837
Sources:
Disc. AE: Premenstrual syndrome, Migraine headache...
Other AEs: Premenstrual syndrome, Migraine headache...
AEs leading to
discontinuation/dose reduction:
Premenstrual syndrome (6.7%)
Migraine headache (1.5%)
Other AEs:
Premenstrual syndrome (13.2%)
Migraine headache (10.7%)
Breast discomfort (8.3%)
Nausea and vomiting (4.5%)
Abdominal discomfort (2.3%)
Mood change (2.3%)
Sources:
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Co-administed with::
ethinylestradiol(20 mug)
Sources:
healthy, mean 25.1 years
n = 220
Health Status: healthy
Age Group: mean 25.1 years
Sex: F
Population Size: 220
Sources:
Disc. AE: Weight gain, Headache...
AEs leading to
discontinuation/dose reduction:
Weight gain (> 0.45)
Headache (> 0.45)
Depression (> 0.45)
Menorrhagia (> 0.45)
Skin disorder (> 0.45)
Emotional lability (> 0.45)
Sources:
AEs

AEs

AESignificanceDosePopulation
Migraine headache 1.5%
Disc. AE
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
healthy, 17 - 40 years
n = 2837
Health Status: healthy
Age Group: 17 - 40 years
Sex: F
Population Size: 2837
Sources:
Migraine headache 10.7%
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
healthy, 17 - 40 years
n = 2837
Health Status: healthy
Age Group: 17 - 40 years
Sex: F
Population Size: 2837
Sources:
Premenstrual syndrome 13.2%
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
healthy, 17 - 40 years
n = 2837
Health Status: healthy
Age Group: 17 - 40 years
Sex: F
Population Size: 2837
Sources:
Abdominal discomfort 2.3%
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
healthy, 17 - 40 years
n = 2837
Health Status: healthy
Age Group: 17 - 40 years
Sex: F
Population Size: 2837
Sources:
Mood change 2.3%
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
healthy, 17 - 40 years
n = 2837
Health Status: healthy
Age Group: 17 - 40 years
Sex: F
Population Size: 2837
Sources:
Nausea and vomiting 4.5%
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
healthy, 17 - 40 years
n = 2837
Health Status: healthy
Age Group: 17 - 40 years
Sex: F
Population Size: 2837
Sources:
Premenstrual syndrome 6.7%
Disc. AE
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
healthy, 17 - 40 years
n = 2837
Health Status: healthy
Age Group: 17 - 40 years
Sex: F
Population Size: 2837
Sources:
Breast discomfort 8.3%
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Sources:
healthy, 17 - 40 years
n = 2837
Health Status: healthy
Age Group: 17 - 40 years
Sex: F
Population Size: 2837
Sources:
Depression > 0.45
Disc. AE
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Co-administed with::
ethinylestradiol(20 mug)
Sources:
healthy, mean 25.1 years
n = 220
Health Status: healthy
Age Group: mean 25.1 years
Sex: F
Population Size: 220
Sources:
Emotional lability > 0.45
Disc. AE
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Co-administed with::
ethinylestradiol(20 mug)
Sources:
healthy, mean 25.1 years
n = 220
Health Status: healthy
Age Group: mean 25.1 years
Sex: F
Population Size: 220
Sources:
Headache > 0.45
Disc. AE
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Co-administed with::
ethinylestradiol(20 mug)
Sources:
healthy, mean 25.1 years
n = 220
Health Status: healthy
Age Group: mean 25.1 years
Sex: F
Population Size: 220
Sources:
Menorrhagia > 0.45
Disc. AE
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Co-administed with::
ethinylestradiol(20 mug)
Sources:
healthy, mean 25.1 years
n = 220
Health Status: healthy
Age Group: mean 25.1 years
Sex: F
Population Size: 220
Sources:
Skin disorder > 0.45
Disc. AE
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Co-administed with::
ethinylestradiol(20 mug)
Sources:
healthy, mean 25.1 years
n = 220
Health Status: healthy
Age Group: mean 25.1 years
Sex: F
Population Size: 220
Sources:
Weight gain > 0.45
Disc. AE
3 mg 1 times / day steady, oral
Recommended
Dose: 3 mg, 1 times / day
Route: oral
Route: steady
Dose: 3 mg, 1 times / day
Co-administed with::
ethinylestradiol(20 mug)
Sources:
healthy, mean 25.1 years
n = 220
Health Status: healthy
Age Group: mean 25.1 years
Sex: F
Population Size: 220
Sources:
Overview

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
minimum
minimum
moderate [IC50 31200 uM]
no (co-administration study)
Comment: "IC50 units given are ""mM""; no significant effect of DRSP on the systemic clearance of the CYP3A4 product omeprazole sulfone was found"
Page: 25.0
moderate [IC50 36500 uM]
yes [IC50 14500 uM]
yes [IC50 3390 uM]
no (co-administration study)
Comment: "IC50 units given are ""mM""; daily oral administration of 3 mg DRSP for 14 days did not affect the oral clearance of omeprazole (40 mg, single oral dose) and the CYP2C19 product 5-hydroxy omeprazole"
Page: 25.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
no (co-administration study)
Comment: simvastatin is not expected to affect DRSP's metabolism; When tested with midazolam, PK parameters of midazolam were similar regardless whether it was dosed with DSRP or with placebo.
Page: 25.0
PubMed

PubMed

TitleDatePubMed
Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive.
2003
New progestogens: a review of their effects in perimenopausal and postmenopausal women.
2004
Safety of a new oral contraceptive containing drospirenone.
2004
Progestogens in combined oral contraceptives for contraception.
2004
Enhancing oral contraceptive success: the potential of new formulations.
2004 Apr
Ethinylestradiol-drospirenone, flutamide-metformin, or both for adolescents and women with hyperinsulinemic hyperandrogenism: opposite effects on adipocytokines and body adiposity.
2004 Apr
Pharmacological profile of progestins.
2004 Apr 15
Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment.
2004 Aug
Flutamide-metformin plus an oral contraceptive (OC) for young women with polycystic ovary syndrome: switch from third- to fourth-generation OC reduces body adiposity.
2004 Aug
An observational study of Yasmin in the management of women with polycystic ovary syndrome.
2004 Jul
Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens.
2004 Jun
Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study.
2004 Jun
Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis.
2004 Mar
[Medication of the month. Angeliq: new hormonal therapy of menopause, with antialdosterone and antiandrogenic properties].
2004 Mar
Drospirenone, a progestogen with antimineralocorticoid properties: a short review.
2004 Mar 31
Ethinyl estradiol/drospirenone (Yasmin): a newer oral contraceptive.
2004 May 15
Prothrombotic changes in users of combined oral contraceptives containing drospirenone and cyproterone acetate.
2004 Nov
The effect on cartilage of different forms of application of postmenopausal estrogen therapy: comparison of oral and transdermal therapy.
2004 Nov
Short-term variations in bone remodeling markers of an oral contraception formulation containing 3 mg of drospirenone plus 30 microg of ethinyl estradiol: observational study in young postadolescent women.
2004 Oct
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide.
2004 Sep
Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone.
2004 Sep
New contraception options.
2004 Sep-Oct
Effects of 17beta-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women.
2005 Dec
Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
2005 Dec
Quantitative analysis of gene regulation by seven clinically relevant progestins suggests a highly similar mechanism of action through progesterone receptors in T47D breast cancer cells.
2005 Dec
Drospirenone and PCOS.
2005 Jan
A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 microg on premenstrual symptoms.
2005 Jan
Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density.
2005 Jan
Venous thromboembolism after high-dose chemotherapy in a patient with Hodgkin's lymphoma receiving the new oral contraceptive ethinylestradiol and drospirenone ("Yasmine").
2005 Jan
Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of metformin at the start and after more than one year of therapy.
2005 Jan
Prospective study on sexual behavior of women using 30 microg ethinylestradiol and 3 mg drospirenone oral contraceptive.
2005 Jul
Systemic sclerosis following oral contraception.
2005 Jun
Effects of drospirenone/17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women.
2005 Jun
Effects of two combined oral contraceptives containing ethinyl estradiol 20 microg combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism.
2005 Jun
Differential effects of estrogens and progestins on the anticoagulant tissue factor pathway inhibitor in the rat.
2005 Mar
Different oral contraceptives and voice quality--an observational study.
2005 May
Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial.
2005 Nov-Dec
Effects of drospirenone/estrogen combinations on bone metabolism.
2005 Oct
Added benefits of drospirenone for compliance.
2005 Oct
Drospirenone in combination with estrogens: for contraception and hormone replacement therapy.
2005 Oct
Importance of controlling blood pressure.
2005 Oct
Pharmacology of different progestogens: the special case of drospirenone.
2005 Oct
Drospirenone, a progestin with a unique cardiovascular profile, for safe contraception and treatment of menopausal symptoms.
2005 Oct
Gateways to clinical trials.
2005 Sep
Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder.
2005 Sep
Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension.
2005 Sep 27
Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-alpha and the neutrophil/lymphocyte ratio.
2006 Feb
The use of an oral contraceptive containing ethinylestradiol and drospirenone in an extended regimen over 126 days.
2006 Jan
Treating acne with oral contraceptives: use of lower doses.
2006 Jan
New progestagens for contraceptive use.
2006 Mar-Apr
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021355s006lbl.pdf
To prevent pregnancy: One tablet (containing 3 mg drospirenone and 0.03 mg ethinyl estradiol) daily by mouth at the same time every day. To prevent symptoms due to menopause. one tablet (0.25 mg drospirenone/0.5 mg ethinyl estradiol) taken by mouth once daily
Route of Administration: Oral
In Vitro Use Guide
Activity of drospirenone was investigated by transiently transfecting the human MR (pRShMR) and pMMTV-CAT into COS 1 cells. Cells were treated with 10 nmol/l aldosterone and, in addition, with increasing amounts of the drospirenone (1nM – 1 mkM). After 48 hrs cells were harvested and duplicate dishes were assayed for activity
Name Type Language
DROSPIRENONE
EP   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
DROSPIRENONE [USP MONOGRAPH]
Common Name English
NSC-760103
Code English
DROSPIRENONE [MART.]
Common Name English
DROSPIRENONE COMPONENT OF SAFYRAL
Common Name English
DROSPIRENONE COMPONENT OF YASMIN
Common Name English
(6R,7R,8R,9S,10R,13S,14S,15S,16S,17S)-1,3',4',6,6A,7,8,9,10,11,12,13,14,15,15A,16-HEXADECAHYDRO-10,13-DIMETHYLSPIRO-(17H-DICYCLOPROPA(6,7:15,16)CYCLOPENTA(A)PHENANTHRENE-17,2'(5'H)-FURAN)-3,5'(2H)-DIONE
Common Name English
DROSPIRENONE COMPONENT OF NEXTSTELLIS
Brand Name English
DROSPIRENONE COMPONENT OF YAZ
Common Name English
DROSPIRENONE [MI]
Common Name English
SLYND
Brand Name English
DROSPIRENONE [INN]
Common Name English
ANGELIQ COMPONENT DROSPIRENONE
Common Name English
ZK-30595
Code English
DROSPIRENONE [USP-RS]
Common Name English
YASMIN COMPONENT DROSPIRENONE
Common Name English
YAZ COMPONENT DROSPIRENONE
Common Name English
BEYAZ COMPONENT DROSPIRENONE
Common Name English
DROSPIRENONE [JAN]
Common Name English
DROSPIRENONE [EP MONOGRAPH]
Common Name English
DROSPIRENONE COMPONENT OF BEYAZ
Common Name English
SAFYRAL COMPONENT DROSPIRENONE
Common Name English
DROSPIRENONE [WHO-DD]
Common Name English
DROSPIRENONE COMPONENT OF ANGELIQ
Common Name English
DROSPIRENONE [USAN]
Common Name English
DROSPIRENONE [VANDF]
Common Name English
17-HYDROXY-6.BETA.,7.BETA.:15.BETA.,16.BETA.-DIMETHYLENE-3-OXO-17.ALPHA.-PREGN-4-ENE-21-CARBOXYLIC ACID, .GAMMA.-LACTONE
Common Name English
ZK 30595
Code English
DROSPIRENONE [ORANGE BOOK]
Common Name English
NEXTSTELLIS COMPONENT DROSPIRENONE
Brand Name English
DRSP
Common Name English
Classification Tree Code System Code
WHO-ATC G03AC10
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
WHO-ATC G03AA12
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
NDF-RT N0000011301
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
NDF-RT N0000175602
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
LIVERTOX 333
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
WHO-ATC G03FA17
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
NCI_THESAURUS C776
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
WHO-VATC QG03FA17
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
WHO-VATC QG03AA12
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
Code System Code Type Description
INN
6519
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
PRIMARY
RXCUI
11636
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C47502
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
PRIMARY
CAS
67392-87-4
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
PRIMARY
LACTMED
Drospirenone
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
PRIMARY
FDA UNII
N295J34A25
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
PRIMARY
IUPHAR
2874
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
PRIMARY
EVMPD
SUB06413MIG
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
PRIMARY
MERCK INDEX
M4772
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
PRIMARY Merck Index
WIKIPEDIA
Drospirenone
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
PRIMARY
EPA CompTox
67392-87-4
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
PRIMARY
PUBCHEM
68873
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
PRIMARY
ECHA (EC/EINECS)
266-679-2
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
PRIMARY
DRUG BANK
DB01395
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
PRIMARY
USP_CATALOG
1229409
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
PRIMARY USP-RS
HSDB
7896
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
PRIMARY
DRUG CENTRAL
968
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
PRIMARY
MESH
C035144
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
PRIMARY
ChEMBL
CHEMBL1509
Created by admin on Fri Jun 25 21:04:26 UTC 2021 , Edited by admin on Fri Jun 25 21:04:26 UTC 2021
PRIMARY